The right drug and the right dose

Journal of Hypertension, Supplement

Volumn 21, Issue 2, 2003, Pages

  Struijker Boudier, Harry A J ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

adrenoceptor blocker; blocker; Angiotensin converting enzyme inhibitor; Angiotensin II receptor antagonist; Antihypertensive; Blood pressure; Calcium channel blocker; Diuretic

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; EPROSARTAN; IRBESARTAN; LOSARTAN; OLMESARTAN; PROPRANOLOL; SARALASIN; TELMISARTAN; VALSARTAN;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; LOW DRUG DOSE; PRIORITY JOURNAL; SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERTENSION; PATIENT SELECTION;

EID: 0041866612     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157:2413-2446.
2. Guidelines subcommittee for the World Health Organization - International Society of Hypertension (WHO-ISH) Mild Hypertension Liaison Committee. 1999 World Health Organization - International Society of Hypertension guidelines for the management of hypertension. J H ypertens 1999; 17:151-183.
3. Moser M. Historical perspective on the management of hypertension. Am J Med 1986; 80:1-11.
4. Prichard BNC. Propranolol and β-adrenergic receptor blocking drugs in the treatment of hypertension. Br J Clin Pharmacol 1982; 13:51-60.
5. Weber MA. Sympathetic nervous system and hypertension. Am J Hypertens 1989; 2(3 Part 2):147-152.
6. Furberg CT, Psaty BM, Pahor M, Alderman MH. Clinical implications of recent findings from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) and other studies of hypertension. Ann Intern Med 2001; 135:1074-1078.
7. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356:359-365.
8. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C, Furberg CD. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies; a meta-analysis of randomised controlled trials. Lancet 2000; 356:1949-1954.
9. Hall WD. A rational approach to the treatment of hypertension in special populations. Am Fam Physician 1999; 60:156-162.
10. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin converting enzyme inhibitors. Pharmacol Rev 1995; 47:25-49.
11. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355:637-645.
12. Karlberg BE. Cough and inhibition of the renin-angiotensin system. J Hypertens 1993; 11(suppl 3):46-52.
13. Brunner HR, Gavras H, Laragh JH. Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure. Lancet 1973; 2:1045-1048.
14. Gavras H, Flessas A, Ryan TJ, Brunner HR, Faxon DP, Gavras I. Angiotensin II inhibition. Treatment of congestive cardiac failure in a high-renin hypertension. JAMA 1977; 238:880-882.
15. Kang PM, Landau AJ, Eberhardt RT, Frishman WH. Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system. Am Heart J 1994; 127:1388-1401.
16. Zanchetti A, Omboni S, Di Biagio C. Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11(suppl 2);57-59.
17. Stumpe KO, Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens 2002; 16(suppl 2):24-28.
18. Mackenzie HS, Ziai F, Omer SA, Nadim MK, Taal MW. Angiotensin receptor blockers in chronic renal disease: the promise of a bright clinical future. J Am Soc Nephrol 1999; 10(Suppl 12):283-286.
19. Brunner HR. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. J Hum Hypertens 2002; 16(suppl 2):13-16.
20. Dickstein K. ELITE II and Val-HeFT are different trials: together what do they tell us? Curr Control Trials Cardiovasc Med 2001; 2:240-243.
21. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For End-point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:1004-1010.
22. Neaton JD, Grimm RH, Prineas RJ, Stamler J, Grandits GA, Elme PJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993; 270:713-724.
23. Perry HM, Bingham S, Horney A, Rutan G, Sambhi M, Carmody S, Collins J. Antihypertensive efficacy of treatment regimens used in veterans administration hypertension clinics. Hypertension 1998; 31:771-779.
24. Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens 2002; 19(suppl 1):49-56.
25. Staessen JA, Wang J-G, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358:1305-1315.
26. Staessen JA, Wang J-G, Thijs L. Calcium-channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. Am J Hypertens 2002; 15(7 Part 2):85-93.
27. Ross SD, Akhras KS, Zhang S, Rozinsky M, Nalysnyk L. Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis. Pharmacotherapy 2001; 21:940-953.
28. Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf 1999; 21:23-33.
29. McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001; 23:833-850.
30. Shusterman NH. Safety and efficacy of eprosartan, a new angiotensin II receptor blocker. Am Heart J 1999; 138(3 Part 2):238-245.
31. Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther 2001; 23:1999-2010.
32. Benet LZ, Kroetz DL, Sheiner LB. Pharmacokinetics, the dynamics of drug absorption, distribution and elimination. In Hardman JG, Limbird LE (editors): Goodman & Gilman. The pharmacological basis of therapeutics. New York: McGraw-Hill; 1996, pp. 3-27.
33. Dina R, Jafari M. Angiotensin II-receptor antagonists: an overview. Am J Health Syst Pharm 2000; 57:1231-1238.
34. Psaty BM, Smith NL, Heckbert SR, Vos HL, Lemaitre RN, Reiner AP, et al. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 2002; 287:1680-1689.
35. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elomfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762.